Literature DB >> 33171485

Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells.

Diana Hanekamp1, Lok Lam Ngai1, Jeroen J W M Janssen1, Arjan van de Loosdrecht1, Gert J Ossenkoppele1, Jacqueline Cloos1.   

Abstract

Entities:  

Year:  2021        PMID: 33171485     DOI: 10.1182/blood.2020007150

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  2 in total

1.  2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.

Authors:  Michael Heuser; Sylvie D Freeman; Gert J Ossenkoppele; Francesco Buccisano; Christopher S Hourigan; Lok Lam Ngai; Jesse M Tettero; Costa Bachas; Constance Baer; Marie-Christine Béné; Veit Bücklein; Anna Czyz; Barbara Denys; Richard Dillon; Michaela Feuring-Buske; Monica L Guzman; Torsten Haferlach; Lina Han; Julia K Herzig; Jeffrey L Jorgensen; Wolfgang Kern; Marina Y Konopleva; Francis Lacombe; Marta Libura; Agata Majchrzak; Luca Maurillo; Yishai Ofran; Jan Philippe; Adriana Plesa; Claude Preudhomme; Farhad Ravandi; Christophe Roumier; Marion Subklewe; Felicitas Thol; Arjan A van de Loosdrecht; Bert A van der Reijden; Adriano Venditti; Agnieszka Wierzbowska; Peter J M Valk; Brent L Wood; Roland B Walter; Christian Thiede; Konstanze Döhner; Gail J Roboz; Jacqueline Cloos
Journal:  Blood       Date:  2021-12-30       Impact factor: 22.113

2.  The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzed.

Authors:  Katerina Bakunina; Hein Putter; Jurjen Versluis; Eva A S Koster; Bronno van der Holt; Markus G Manz; Dimitri A Breems; Bjorn T Gjertsen; Jacqueline Cloos; Peter J M Valk; Jakob Passweg; Thomas Pabst; Gert J Ossenkoppele; Bob Löwenberg; Jan J Cornelissen; Liesbeth C de Wreede
Journal:  Cancer Med       Date:  2021-12-24       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.